Happy Mother's Day! Taking A Look Ahead Watching and

New Post Public Reply Private Reply Replies (3) Message Board
MGK_2
680
Happy Mother's Day!

Taking A Look Ahead

Watching and waiting. Not just waiting, but also watching and stating what I see. Others too, who watch, as do I can see where we are headed.

Nader was put out, like unto death but not unto death. He had not been able to further himself regardless of the weapon he wielded. He had an inability to fight his foes. He was therefore shut down.

Early celebrations turned dark. The thinking that winning was imminent was hit with RTF and warning letters. Yet, Nader was right on both accounts and they pull ahead on their lies and deception.

Nader escapes by termination. His way out. CytoDyn's way out. Nader's steep monetary draw now eliminated. CytoDyn operates down to the bare minimum. Efficiency rules. We no longer barrel down head long the road with a megaphone announcing every detail and every play. Even the most prized and pertinent details are put away to be appropriately announced at strategic moments. However, what our enemies do not realize remains the same fact that the same power which Nader constantly orated and proclaimed about is the same power which will level them and it grows mightier by the day.

Things are not as it they may appear. Too many would love you to believe that CytoDyn is in dire straights. I believe CytoDyn will say something small about NASH 700 pretty soon. We already know that this will happen in mid-June, but I think we will get something prior to that. It doesn't have to be a complete revelation. It can be partial. Just need to keep them off our backs. We need them to have a taste of the bomb blast that's coming. Just give us a taste CytoDyn, we don't need to eat.

On Amarex, I stand by what I said yesterday. We won't negotiate. There is much behind the BLA they submitted to the FDA on our behalf for the HIV indication. There are perpetrators and big money as well as big pharma behind this act of maleficence. None are immune. All have deep pockets. All will be found out and discovered. The implications of which are enormous. CytoDyn swallows whole the elephant in the room. Negotiations? There will be nothing left to negotiate for, not even half an ear. No crumbs under the table. And Amarex will not be the only one consumed.

It seems like the waters are calm for big pharma's ship. It's smooth sailing right now. All they need to do is to continue to pay interest on the borrowed short shares and they will succeed on keeping the lid on leronlimab. Just, maintain at least the 50 million short shares, keeping the cork in the bottle and keep adding even more than 80% of daily trades as short. Do what ever it takes to keep this thing from blowing, even when the bottle is shaken, when the world wants in, and certainly, do what ever has to be done to keep this pressure cooker down. Therefore do it, they command to their brokers, short it, as long as the word Leronlimab is kept at bay.

CytoDyn shall speak and the bottle shakes. CytoDyn already know what they will say. That time soon approaches.

Sidley Austin shall speak. Their time comes, and is beyond the horizon.

Either one of these or the culmination of the two, but I think it will be sudden rather than a slow upward drip. A sudden spoken word, apt & apropos, brings on the sudden collapse of this tall stack of short suppressive shares and the elimination of any attack and the evaporation of the worst of them as CytoDyn will have engorged itself in their plunder.

That's my conclusion when it comes to Amarex and NASH.

//

Now onto partnerships.

Just to remind you all. I speak with confidence because we own Leronlimab. I have no other reason to be confident other than solely on account of our asset. I take my forwardness because of that drug.

Unless Amarex concludes rapidly and we are awarded a massive windfall, (which I do not perceive happening all that soon, but I know it will come), CytoDyn needs to partner. CytoDyn needs to remain in control of all the partnerships it engages into. The partner needs to understand that it is their privilege to partner with CytoDyn, because Leronlimab causes their drug to be successful. CytoDyn must maintain ownership of the molecule. All partnerships terminate once their drug goes generic. After that, doctors may prescribe their drug alone, Leronlimab alone or still the combination of the drug/the generic with Leronlimab.

Partnerships are the only way, without a massive windfall, to go forward. And that is why I think we need a CEO who already has experience with many big pharmaceuticals and who is respected by them. and who has pertinent contacts with them or he may know many of the pharmaceutical suppliers and supporters and be well credentialed. It will be through this person, that CytoDyn develops into a Big Pharma itself and within his tenure, that CytoDyn greatly expands and morphs into adulthood.

Obstacles? Road blocks? Detours? No. There won't be any.

Everyone will want to be paired up with Leronlimab and that is our opportunity to expand our indication list. Big Pharma's mantra will be, "If you can't beat 'em, join 'em." If you can't beat Leronlimab, then partner with it. CytoDyn decisively takes market share. Shorts will have found greener pastures for months and months already.

CytoDyn needs to remain vigilant. Be careful of the covenants you sign CytoDyn. Leronlimab may not be breached. That must be forbidden. There can be no access to its assembly or manufacturing. There can be no understanding to its formula. There can be no decoding.

If for whatever reason, this is actually breached. all contracts / partnerships cease at once and CytoDyn goes it alone again. That must be written in every contract. Whoever would have breached this will be fighting with their best foot forward to again destroy CytoDyn.



Hope we hear from CytoDyn shortly.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viam and NYC FIRST: A Robotics Education Revolution

Updated Category News Views 60

Redefining Robotics Education in New York City Schools What happens when you blend tech innovation with education? Well, in the heart of New York City, Viam and NYC FIRST are shaking up the robotics scene. It's like introducing kids to an entirely new world where they can roll up their sleeves and tinker with tomorrow's technology today. It's about making robotics...

Continue Reading
Noah's Q3 2026 Earnings: What Investors Should Watch

Updated Category News Views 29

Anticipation Builds for Noah's Earnings Report A penny for your thoughts? More like a truckload for some insights on Noah Holdings (NYSE: NOAH). They’re taking the stage to drop their Q3 2026 earnings on November 24, after the markets put their feet up. If you're tracking global wealth managers, especially those dancing on the NYSE and the Hong Kong Stock Exchange...

Continue Reading
Yancheng's Harmony: Wetlands Embrace Future Growth

Updated Category News Views 100

Yancheng Wetlands: A Masterclass in Nature and Progress Sometimes, you come across a story that blends an old-school respect for nature with cutting-edge progress—Yancheng's wetlands are the real deal. Ten thousand years ago, this land was swallowed by the sea. Fast forward to the present, and you'll find 520,000 hectares of wetlands teeming with life, hosting over...

Continue Reading
Huawei Shakes Up Home Energy With LUTERRA S2

Updated Category News Views 115

Welcome to the Future of Home Energy If you thought home energy systems couldn't get any slicker, Huawei's got news for you. They just dropped the LUTERRA S2, a swanky, all-in-one residential energy system that's about to put your old setup to shame. This ain’t your granddad's inverter. We're talking hybrid functionality with storage and AI-driven energy management...

Continue Reading
Envision Energizes Türkiye's Green Power Future Ambitions

Updated Category News Views 93

Türkiye's Energy Vision Gains Momentum When you talk about energy transition, you can't ignore Türkiye's ambitious plans. Türkiye's Energy Minister, H.E. Alparslan Bayraktar, is rolling up his sleeves for a bold push into renewables. On the sidelines of COP31, he sat down with Envision Energy's main dealmaker, Kane Xu, to chew over how they can power up Türkiye’s...

Continue Reading
Lument Finance's Q3 2026 Numbers: A Critical Analysis

Updated Category News Views 45

LFT Posts Significant Loss in Q3 2026 It's third quarter earnings season, and Lument Finance Trust, Inc. (NYSE: LFT) is out here making headlines for all the wrong reasons. We're talking about a whopper of a GAAP net loss totalling $13.5 million—yep, you read that right—equating to a bruising $2.57 per share. Frankly, in this business, such numbers are akin to a...

Continue Reading
Candy Crush Celebrates XBOX: A Playful Nostalgic Twist

Updated Category News Views 16

When Candy Brands Meet Gaming Legends Who would have thought a saccharine mobile game could bring heavy-hitting franchises like Halo and DOOM to the soft world of candies? But that's exactly what Candy Crush Saga is doing to mark XBOX's 25th anniversary. This celebration isn't just about nostalgia—it's about making a splash in both the gaming and mobile app markets, and...

Continue Reading
NYSE Gains Ground with Historic Listings Transfers

Updated Category News Views 50

You'll know it's a topsy-turvy market when hefty firms start switching their stock exchange allegiance. This year, nine noteworthy companies, with a collective market heft of nearly half a trillion dollars, kissed Nasdaq goodbye and nestled into the New York Stock Exchange (NYSE). Now, why would these big shots make the shift, you ask? Let's dive into the nitty-gritty....

Continue Reading
Portillo's Faces Class Action Over Rapid Expansion

Updated Category News Views 0

Trouble Brews Over at Portillo's Inc. Here's a classic case of biting off more than one can chew. Portillo's Inc., known for its Chicago-style eats, is now facing the music for what seems to be an overly ambitious strategy. The San Diego-based law firm Robbins LLP has filed a class action lawsuit on behalf of all who've invested in this restaurant chain's stock between...

Continue Reading
UN Urges Real Progress on Climate at COP31 Summit

Updated Category News Views 36

When it comes to global climate action, meetings like the COP31 summit aren’t just another day in the office. Today, in Antalya, Türkiye, the talk was big, but the stakes are even bigger as business and UN leaders grappled with the nagging gap between corporate commitments and actual emissions reductions. The Urgency of 1.5°C Folks, we're skating on thin ice here with...

Continue Reading

Top 5 Most Recently Viewed Articles

Fuji Soft's Decision Amidst Competing Offers Explained

Updated Category News Views 115

Fuji Soft Inc. found itself in the thick of a bidding war back in 2024, grappling with two major offers for its shares. The board decided to endorse KKR & Co.'s tender offer even after Bain Capital stepped in with a juicier bid of ¥9,450 (around $63) per share, leaving many traders scratching their heads. Board's Backing: A Risky Gamble? The board's pledge to recommend...

Continue Reading
Miss Peaches and Spirit of Gallo Join Forces for a Cause

Updated Category News Views 677

Miss Peaches Collaborates with Spirit of Gallo The well-known 'furfluencer' Miss Peaches has partnered with Spirit of Gallo to introduce a unique product: Lucky One Lemonade. This innovative hard lemonade is crafted from premium vodka and boasts a non-carbonated formula, making it a standout option in the hard lemonade category. This initiative focuses on both delivering...

Continue Reading
GSI Technology's Innovative Edge Strategy in Drone Sector Growth

Updated Category News Views 148

Defining the Next Frontier: GSI Technology and Drone Market Growth GSI Technology, Inc. (Nasdaq: GSIT), renowned for its pioneering work with Associative Processing Units (APUs), is on a path to significantly transform the landscape of high-performance compute (HPC) processing. With its recent strategy to penetrate the booming drone market, GSI Technology aims to harness...

Continue Reading
Biohaven's BHV-1300: A Game Changer for Graves' Disease

Updated Category News Views 21

Biohaven's Bold Leap with BHV-1300 Sometimes in the biotech game, you meet a rookie that’s got the goods to shake up the entire league. Enter Biohaven Ltd.’s BHV-1300. It’s not just another player—it’s the first MoDE™ extracellular protein degrader swinging for autoimmune fences. This kid’s got something new up its sleeve, targeting those pesky antibodies...

Continue Reading
Polaris Slingshot Marks 10 Years with Stunning Limited Edition

Updated Category News Views 172

Polaris Slingshot Celebrates a Decade of Driving Innovation For ten incredible years, the Polaris Slingshot has been a sensation, captivating enthusiasts with its audacious design and exhilarating ride. Launched as a revolutionary three-wheeled motorcycle, the Slingshot quickly garnered a devoted fan base across North America and beyond. This year, Polaris is thrilled to...

Continue Reading